Trial Profile
A global analysis of Telavancin activity against Gram-Positive Pathogens isolated from the bone/joint infections across different regions : SENTRY Program collection
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 30 Sep 2016
Price :
$35
*
At a glance
- Drugs Telavancin (Primary)
- Indications Gram-positive infections; Osteomyelitis
- Focus Therapeutic Use